1 week Ago By Defense World Staff
Arrowstreet Capital Limited Partnership bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 28,903 shares of the company’s stock, valued at approximately $770,000.
Arrowstreet Capital Limited Partnership owned approximately 0.10% of Castle Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Other hedge funds also recently bought and sold shares of the company.
JPMorgan Chase & Co. increased its position in shares of Castle Biosciences by 55.5% in the 4th quarter.
JPMorgan Chase & Co. now owns 107,936 shares of the company’s stock valued at $2,876,000 after buying an additional 38,527 shares in the last quarter. EntryPoint Capital LLC increased its holdings in shares of Castle Biosciences by 214.
0% in the fourth quarter. EntryPoint Capital LLC now owns 29,144 shares of the company’s stock worth $777,000 after acquiring an additional 19,862 shares in the last quarter. Perkins Capital Management Inc.
increased its holdings in shares of Castle Biosciences by 4.7% in the fourth quarter. Perkins Capital Management Inc.
now owns 34,165 shares of the company’s stock worth $910,000 after acquiring an additional 1,525 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Castle Biosciences by 4.
8% during the fourth quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company’s stock worth $48,837,000 after purchasing an additional 83,783 shares during the period.
Finally, Fox Run Management L.L.C.
bought a new position in shares of Castle Biosciences during the 4th quarter valued at about $286,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Castle Biosciences Trading Up 2.1 %Castle Biosciences stock opened at $19.70 on Friday.
The company has a debt-to-equity ratio of 0.02, a current ratio of 7.78 and a quick ratio of 7.
64. The firm has a 50-day moving average of $22.34 and a 200-day moving average of $27.
10. The company has a market cap of $568.13 million, a price-to-earnings ratio of 98.
50 and a beta of 1.11. Castle Biosciences, Inc.
has a one year low of $16.97 and a one year high of $35.84.
Wall Street Analyst Weigh InCSTL has been the topic of several research analyst reports. Robert W. Baird raised their target price on shares of Castle Biosciences from $36.
00 to $37.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Stephens restated an “overweight” rating and set a $41.
00 price objective on shares of Castle Biosciences in a report on Thursday, January 2nd. Finally, Guggenheim set a $30.00 target price on Castle Biosciences and gave the stock a “buy” rating in a report on Friday, March 28th.
Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Castle Biosciences currently has an average rating of “Buy” and an average price target of $38.75.
Check Out Our Latest Analysis on CSTLInsider Activity at Castle BiosciencesIn related news, Director Daniel Bradbury sold 7,867 shares of Castle Biosciences stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.
39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Derek J.
Maetzold sold 986 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.03, for a total value of $27,637.
58. Following the completion of the sale, the insider now owns 80,818 shares in the company, valued at $2,265,328.54.
This represents a 1.21 % decrease in their position. The disclosure for this sale can be found here.
Over the last ninety days, insiders sold 35,071 shares of company stock valued at $775,682. Insiders own 7.20% of the company’s stock.
Castle Biosciences Profile (Free Report)Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.Featured StoriesFive stocks we like better than Castle BiosciencesWhat Is WallStreetBets and What Stocks Are They Targeting?Robinhood Strategies Could Be a Game-Changer for Young Investors3 Stocks to Consider Buying in OctoberAre These 3 Retail Stocks Oversold or Really in Trouble?What is the S&P/TSX Index?IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are AheadWant to see what other hedge funds are holding CSTL? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report)..
